Angiocrine Bioscience is a private, clinical-stage cell and gene therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions.

Biotechnology

Angiocrine Bioscience

Paul Finnegan

Doreen G.

Geoff Davis

Margie Breneman

John R. Jaskowiak

Lee Landeen

John Lomoro

John K. Fraser

Shawn Sheeron

Jeannette Filippone

Daniel J. Nolan

Michael Ginsberg

The executive team at Angiocrine Bioscience has a history of experience in the science, finance, and pharmaceutical industries. Many members of the team have worked together at previous companies, such as StemSource/Macropore Biosurgery/Cytori Therapeutics, Kyriba Corporation, and Transdel Pharmaceuticals, Inc. The team is also well-educated, with degrees in fields such as Hematopoietic Stem Cell Biology, Biochemistry/Physiology, and Accounting.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Angiocrine Bioscience

Leadership Team

Board of Directors